ArticleScientific reports2026
The baseline vitreous proteome in rhegmatogenous retinal detachment: a case-control study of proliferative vitreoretinopathy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proliferative vitreoretinopathy (PVR) is the leading cause of failure after rhegmatogenous retinal detachment (RRD) repair, yet no baseline biomarkers exist to stratify risk. In this retrospective, nested case-control study we asked whether the vitreous proteome at the time of primary RRD repair predicts subsequent PVR. Undiluted vitreous (1.0 mL) was obtained by pars plana vitrectomy from 16 eyes of 16 patients (8 who later developed PVR and 8 matched RRD controls) and analyzed by tandem mass tag (TMT)-multiplexed liquid chromatography-tandem mass spectrometry. Of 918 proteins identified, 876 were retained after contaminant filtering. After Benjamini-Hochberg correction for multiple comparisons, no proteins were differentially expressed between cases and controls. Six proteins (decorin, arrestin-C, pre-mRNA processing factor 6, C-reactive protein, fructose-1,6-bisphosphatase 1 and an immunoglobulin kappa variable chain) reached nominal significance (p < 0.05) but did not survive correction. The most abundant vitreous constituents included albumin, retinol-binding protein 4 and serotransferrin. In this limited cohort, no large or statistically robust baseline proteomic differences were detected between eyes that subsequently developed PVR and matched controls. We hypothesize that the molecular drivers of PVR may emerge postoperatively rather than being present at the time of the index detachment, although larger studies will be required to confirm or refute this possibility. Data are available via ProteomeXchange with identifier PXD077831.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.